Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Gaza Ceasefire Failure Risks Permanent Division, U.N. Warns 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Pentagon Expands AI Model Testing as It Seeks Alternatives to Anthropic’s Claude 
Why the future of marijuana legalization remains hazy despite high public support 
U.S. Removes Francesca Albanese From Sanctions List After Court Ruling 
China to Buy 200 Boeing Jets, Push for Extended U.S. Trade Deal 
Raul Castro Indicted by U.S.: Cuba’s Revolutionary Leader Faces Renewed Scrutiny in 2026 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Trump to Swear In Kevin Warsh as New Federal Reserve Chair Amid Inflation Concerns 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
